Aloxi

Aloxi,

a trademark for palonosetron.

palonosetron hydrochloride

Aloxi

Pharmacologic class: Selective serotonin subtype 3 (5-HT₃) receptor antagonist

Therapeutic class: Antiemetic

Pregnancy risk category B

Action

Selectively binds to and antagonizes 5-HT₃ receptors on vagal nerve terminals and in chemoreceptor trigger zone. This action blocks serotonin release, reducing the vomiting reflex.

Availability

Solution: 0.25 mg (free base) in 5-ml vial

⊘Indications and dosages

➣ To prevent nausea and vomiting caused by cancer chemotherapy

Adults: 0.25 mg I.V. as a single dose 30 minutes before chemotherapy. Repeated doses within 7 days aren't recommended.

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:
• hypersensitivity to other 5-HT₃ receptor antagonists
• diabetes mellitus, hepatic dysfunction
• pregnant or breastfeeding patients
• children.

Administration

• Flush I.V. line with normal saline solution before and after giving.
• Deliver into I.V. line over 30 seconds. Don't mix with other drugs.

Route	Onset	Peak	Duration
I.V.	Unknown	Unknown	Unknown

Adverse reactions

CNS: headache, fatigue, insomnia, dizziness, anxiety

CV: hypotension, vein discoloration and distention, nonsustained tachycardia, bradycardia

GI: constipation, diarrhea, abdominal pain, anorexia

GU: glycosuria

Metabolic: fluctuating electrolyte levels, hyperglycemia, metabolic acidosis, hyperkalemia

Musculoskeletal: joint pain

Other: fever, flulike symptoms

Interactions

Drug-diagnostic tests: Alanine aminotransferase, aspartate aminotransferase, bilirubin, blood and urine glucose, potassium: increased levels

Patient monitoring

• Monitor vital signs and ECG. Watch closely for tachycardia, bradycardia, and hypotension.
• Watch electrolyte levels for fluctuations (especially hyperkalemia and metabolic acidosis).
• Evaluate temperature. Stay alert for flulike symptoms.
• Closely monitor blood and urine glucose levels in diabetic patients. Stay alert for hyperglycemia.

Patient teaching

• Explain that drug helps prevent nausea and vomiting caused by chemotherapy.
• Teach patient to recognize and report signs and symptoms of hyperkalemia and metabolic acidosis.
• Advise patient to report flulike symptoms.
• Instruct diabetic patient to closely watch blood and urine glucose levels.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

Mentioned in	?		References in periodicals archive	?		Medical browser	?		Full browser	?
palonosetron hydrochloride	8 million in the same period in 2005, primarily due to the deployment and expansion of the acute care field organization, investment in the Aloxi brand, and increased administrative costs. MGI PHARMA REPORTS FIRST QTR '06 TOTAL REVENUE OF $78.2 MIL by Biotech Financial Reports Helsinn and Biovitrum enter a license agreement for Nordic marketing of Aloxi, a drug that prevents nausea and vomiting in cancer patients Helsinn Healthcare SA, Switzerland and Biovitrum AB, Sweden have signed an agreement granting Biovitrum the exclusive license and distribution rights of Aloxi (Palonosetron hydrochloride) in the Nordic territory. HELSINN/BIOVITRUM SIGN LICENSE PACT FOR ALOXI MARKETING by Worldwide Biotech Aloxi, the response rates for APF530 10 mg dose were higher than Aloxi in all nine analyses for moderately emetogenic chemotherapy and in five of nine analyses for highly emetogenic chemotherapy. A.P. Pharma Reports Results for the Third Quarter 2008 by Business Wire	aloin Alopam alopecia alopecia areata alopecia capitis totalis alopecia circumscripta alopecia congenitalis alopecia hereditaria alopecia liminaris frontalis alopecia medicamentosa alopecia neurotica alopecia pityrodes alopecia prematura alopecia senilis alopecia symptomatica alopecia totalis alopecia toxica alopecia universalis alopecic Alopekis Alopex lagopus ALOS alosetron hydrochloride Alouatta Alouattamyia Aloxi Aloysia ALP alpaca Alpers disease Alpers' disease alpestrine clover alpha Alpha 1 -Adrenergic Blockers alpha 1 -antitrypsin alpha 1 -antitrypsin test alpha 1 -proteinase inhibitor alpha 2 -antiplasmin alpha 2 -interferon alpha activity alpha alcoholism alpha angle alpha biofeedback Alpha blockers alpha carbon atom alpha carotene alpha cell alpha chain disease alpha effect alpha error Alpha Eta	Alosetron hydrochloride ALOSH Alost Alost Alot Alotau, Papua New Guinea - Gurney ALOTBSOL ALOTS Alottment Alottment Alottment Alouatta Alouatta Alouatta Alouattamyia Alouattinae Alouattinae Alouattinae aloud aloud aloud Alouette River Management Society Alouion Alouion Aloung P'Houra Alompra Alov, Aleksandr Alov, Aleksandr Aleksandrovich ALOW ALOW ALOX Aloxi Aloyisus Leon Higginbotham Aloys Blumauer Aloys Haba Aloys Hába Aloys Senefelder Aloys Senefelder Aloys Sprenger Aloysia Aloysia citriodora Aloysia citriodora Aloysia triphylla Aloysia triphylla Aloysians and Partners in North America Aloysius Aloysius Aloysius Butler & Clark Aloysius, Saint alp alp alp alp ALP (Australia) Alp Arsalan Alp Arslan Alp Arslan, Muhammad Ibn Daud Alp-Arslan Alp-Tegin ALPA ALPA Alpa-MSE

Mentioned in

References in periodicals archive

Medical browser

Full browser

palonosetron hydrochloride

8 million in the same period in 2005, primarily due to the deployment and expansion of the acute care field organization, investment in the Aloxi brand, and increased administrative costs.

MGI PHARMA REPORTS FIRST QTR '06 TOTAL REVENUE OF $78.2 MIL by Biotech Financial Reports

Helsinn and Biovitrum enter a license agreement for Nordic marketing of Aloxi, a drug that prevents nausea and vomiting in cancer patients Helsinn Healthcare SA, Switzerland and Biovitrum AB, Sweden have signed an agreement granting Biovitrum the exclusive license and distribution rights of Aloxi (Palonosetron hydrochloride) in the Nordic territory.

HELSINN/BIOVITRUM SIGN LICENSE PACT FOR ALOXI MARKETING by Worldwide Biotech

Aloxi, the response rates for APF530 10 mg dose were higher than Aloxi in all nine analyses for moderately emetogenic chemotherapy and in five of nine analyses for highly emetogenic chemotherapy.

A.P. Pharma Reports Results for the Third Quarter 2008 by Business Wire